Compare Stocks → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:APTONASDAQ:ATRANASDAQ:AVRONASDAQ:OYSTNASDAQ:PRTO Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPTOAptose Biosciences$1.25+1.3%$1.60$1.20▼$8.70$19.58M1.2987,608 shs37,984 shsATRAAtara Biotherapeutics$0.70+0.6%$0.72$0.20▼$3.02$83.71M0.692.71 million shs192,015 shsAVROAVROBIO$1.21+0.8%$1.28$0.57▼$1.70$54.28M1.22271,246 shs6,584 shsOYSTOyster Point Pharma$11.17$11.15$3.46▼$19.00$299.85M1.31212,171 shs330 shsPRTOProteon Therapeutics$3.05+15.5%$19.37$0.22▼$3.94$67.65M0.61.11 million shs536,534 shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPTOAptose Biosciences-0.08%-5.38%-20.65%-34.75%-83.09%ATRAAtara Biotherapeutics+5.51%+2.77%0.00%+16.04%-77.06%AVROAVROBIO0.00%-4.76%-6.25%-9.77%+27.06%OYSTOyster Point Pharma0.00%0.00%0.00%0.00%0.00%PRTOProteon Therapeutics+15.53%+7.39%-24.13%+63.98%-13.11%$25,000 into $109,616 in two months? (Ad)Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPTOAptose Biosciences1.1207 of 5 stars3.53.00.00.00.60.00.6ATRAAtara Biotherapeutics3.8693 of 5 stars3.02.00.04.72.62.50.6AVROAVROBIO1.1846 of 5 stars3.03.00.00.00.61.70.6OYSTOyster Point PharmaN/AN/AN/AN/AN/AN/AN/AN/APRTOProteon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPTOAptose Biosciences3.00Buy$19.801,489.72% UpsideATRAAtara Biotherapeutics2.00Hold$28.003,892.59% UpsideAVROAVROBIO2.00Hold$2.0065.29% UpsideOYSTOyster Point PharmaN/AN/AN/AN/APRTOProteon TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest ATRA, AVRO, PRTO, APTO, and OYST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/3/2024APTOAptose BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$5.003/27/2024APTOAptose BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.002/1/2024APTOAptose BiosciencesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.00 ➝ $5.00(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPTOAptose BiosciencesN/AN/AN/AN/A($0.19) per shareN/AATRAAtara Biotherapeutics$8.57M9.77N/AN/A($0.97) per share-0.72AVROAVROBION/AN/A$0.29 per share4.19$2.13 per shareN/AOYSTOyster Point Pharma$24.54M12.22N/AN/A$3.80 per share2.94PRTOProteon TherapeuticsN/AN/AN/AN/A($0.06) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPTOAptose Biosciences-$51.21M-$7.72N/AN/AN/AN/A-458.70%-205.30%5/13/2024 (Estimated)ATRAAtara Biotherapeutics-$276.13M-$2.62N/AN/AN/A-3,220.88%-783.31%-122.34%5/13/2024 (Estimated)AVROAVROBIO$12.16M-$0.10N/AN/AN/AN/A-74.86%-65.11%5/9/2024 (Estimated)OYSTOyster Point Pharma-$100.66M-$6.65N/AN/AN/A-901.99%-490.33%-108.29%N/APRTOProteon Therapeutics-$20.73M-$1.15N/AN/AN/AN/AN/A-118.68%N/ALatest ATRA, AVRO, PRTO, APTO, and OYST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023ATRAAtara Biotherapeutics-$0.61-$0.56+$0.05-$0.56$2.45 million$4.25 million3/26/2024Q4 2023APTOAptose Biosciences-$1.48-$1.44+$0.04-$1.44N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPTOAptose BiosciencesN/AN/AN/AN/AN/AATRAAtara BiotherapeuticsN/AN/AN/AN/AN/AAVROAVROBION/AN/AN/AN/AN/AOYSTOyster Point PharmaN/AN/AN/AN/AN/APRTOProteon TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPTOAptose BiosciencesN/A0.780.78ATRAAtara BiotherapeuticsN/A0.720.65AVROAVROBION/A15.7815.78OYSTOyster Point Pharma8.493.353.11PRTOProteon TherapeuticsN/A5.985.98OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPTOAptose Biosciences26.62%ATRAAtara Biotherapeutics70.90%AVROAVROBIO62.63%OYSTOyster Point Pharma96.70%PRTOProteon Therapeutics23.03%Insider OwnershipCompanyInsider OwnershipAPTOAptose Biosciences9.53%ATRAAtara Biotherapeutics4.50%AVROAVROBIO9.20%OYSTOyster Point Pharma17.90%PRTOProteon Therapeutics45.70%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAPTOAptose Biosciences3115.72 million14.22 millionNo DataATRAAtara Biotherapeutics334119.36 million113.99 millionOptionableAVROAVROBIO1344.86 million40.73 millionOptionableOYSTOyster Point Pharma30326.84 million22.04 millionNot OptionablePRTOProteon Therapeutics1722.18 millionN/ANot OptionableATRA, AVRO, PRTO, APTO, and OYST HeadlinesSourceHeadlineiPad Promacrumors.com - February 2 at 5:28 PMEsperion Therapeutics Inc ESPRmorningstar.com - November 5 at 4:53 AMThe Latest Analyst Ratings for Revance Therapeuticsbenzinga.com - September 20 at 8:42 AMENLV - Enlivex Therapeutics Ltd.finance.yahoo.com - June 7 at 12:06 AMPrelude Therapeutics Insider Trades Send a Signalbenzinga.com - May 25 at 3:00 PMGlobal Protein Therapeutics Market Report 2023: Development of Plasma Derived Therapies Drives Growthbenzinga.com - May 23 at 12:25 AMThe best iPhone 14 Pro deals for May 2023techradar.com - May 18 at 8:39 AMRAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meetingbenzinga.com - April 26 at 6:30 PMAdvances in Antibody Therapeuticsthe-scientist.com - April 23 at 4:46 AMEarly Adopter of Remote Therapeutic Monitoring Achieves Significant Clinical and Financial Outcomesbenzinga.com - February 22 at 10:26 AMCadrenal Therapeutics Announces Pricing of Initial Public Offering (IPO)finance.yahoo.com - January 22 at 6:13 PMAdvanced Proteome Therapeutics Announces Its Proposed Plan of Arrangementwsj.com - January 19 at 8:29 PMPeripheral Arterial Disease (PAD) Therapeutics Market 2023 Size & Segmentation Analysis with Share, Trends till 2028 [ NEW REPORT ]marketwatch.com - January 19 at 12:23 AMBusiness & Academia Join Forces To Study Magic Mushroom Therapy For IBS Patientsbenzinga.com - January 3 at 3:29 PMWhat 5 Analyst Ratings Have To Say About PTC Therapeuticsmsn.com - October 17 at 5:53 PMWhat 6 Analyst Ratings Have To Say About Revance Therapeuticsmsn.com - September 22 at 10:23 AMPropella Therapeutics Announces Presentation of Phase 1/2 Data of PRL-02 for the Treatment of Advanced Prostate Cancer at ESMO Congress 2022finance.yahoo.com - September 9 at 4:35 AMProthioneTM Capsules Reduced Time to COVID-19 Clinical Resolution and Decreased Viral Load in Phase II Clinical Trialfinance.yahoo.com - June 15 at 9:31 AMPhysical Rehabilitation Network Expands into Wyomingptproductsonline.com - June 9 at 8:12 AMBristol-Myers To Buy Turning Point Therapeutics In $4.1 Billion Oncology Dealthestreet.com - June 3 at 10:41 PMFlagship Pioneering launches protein startup with $75Mbizjournals.com - May 27 at 6:28 AMProteon Pharma to set up plant in Maharashtrathehindubusinessline.com - April 20 at 11:54 AMProteon Pharmaceuticals appoints sales director for India subcontinent and Southeast Asiaefeedlink.com - March 15 at 7:00 AMProteon Pharmaceuticals appoints Paolo Doncecchi as Global Sales Directorbignewsnetwork.com - January 31 at 11:19 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAptose BiosciencesNASDAQ:APTOAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Atara BiotherapeuticsNASDAQ:ATRAAtara Biotherapeutics, Inc. develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA2271 and ATA3271 to treat mesothelin; and ATA3219 for the treatment of B-cell malignancies, as well as ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center. The company was incorporated in 2012 and is headquartered in Thousand Oaks, California.AVROBIONASDAQ:AVROAVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Oyster Point PharmaNASDAQ:OYSTOyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.Proteon TherapeuticsNASDAQ:PRTOProteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. Its lead product candidate is vonapanitase, an investigational drug intended to enhance hemodialysis vascular access outcomes. The company develops vonapanitase, a recombinant human elastase, which has completed Phase II and Phase III clinical trials for patients with chronic kidney disease. It is also evaluating vonapanitase in a Phase I clinical trial in patients with peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.